Veradermics is a late clinical-stage, dermatologist-founded biopharmaceutical company focused on first-in-class treatments for common dermatologic conditions. Its lead candidate, VDPHL01, is an extended-release, non-hormonal oral minoxidil tablet positioned to become the first FDA-approved oral therapy for pattern hair loss in both women and men. VDPHL01 is currently being evaluated in three Phase 3 trials after encouraging Phase 2 male data showed average hair count increases of 37.5 hairs/cm² at two months and 47.3 hairs/cm² at four months, with 90.5 % of participants reporting improved coverage and no serious adverse events. The formulation aims to sustain minoxidil exposure to follicles while avoiding cardiac risk–related concentration spikes seen in immediate-release versions. Proceeds from the recent financing will fund completion of Phase 3 registrational trials and a planned New Drug Application submission to the FDA. Beyond VDPHL01, Veradermics is building a pipeline of differentiated dermatology products that combine proven mechanisms with innovative delivery technologies to enhance efficacy, safety, and patient convenience.

Total raised

$225M

Funding rounds

2

Latest round

Series C

Latest activity

Oct 2025